American Journal of Roentgenology, Vol 160, 809-812, Copyright © 1993 by American Roentgen Ray Society

ARTICLES

Endometrial abnormalities associated with tamoxifen therapy for breast cancer: sonographic and pathologic correlation

CA Hulka and DA Hall
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.

OBJECTIVE: Tamoxifen is widely used to treat breast carcinoma in postmenopausal women. Previous studies have suggested an increased prevalence of endometrial carcinoma and polyps after treatment with tamoxifen. We correlated findings on pelvic sonograms with pathologic findings in a group of patients treated with tamoxifen. MATERIALS AND METHODS: We reviewed the pelvic sonograms and medical histories of 14 postmenopausal women with breast carcinoma who were being treated with tamoxifen. Pathologic correlation was available in the 11 cases in which adequate tissue was obtained. Coexisting pathologic changes were found in seven patients. Pathologic examination showed a total of 18 endometrial abnormalities, including nine cases of uterine polyps, four cases of hyperplasia, two cases of endometritis, one proliferative endometrium, one inactive endometrium, and one case of carcinoma. RESULTS: Sagittal sonograms of all 11 patients with pathologic correlation showed abnormal endometrial thickening measuring more than 7 mm. The sonographic appearance of the endometrium in these patients included hyperechoic, homogeneous tissue; hyperechoic tissue with multiple, small cystic spaces; heterogeneous tissue with small cystic spaces; and solid tissue that was heterogeneous. Small cystic spaces were seen in all cases of polyps. Six of the nine cases of polyps were associated with other endometrial abnormalities also. The single case of endometrial carcinoma appeared solid and heterogeneous on sonography; however, further pathologic examination of the surgical specimen showed a coexisting polyp. CONCLUSION: Tamoxifen therapy is associated with several findings on sonograms of the uterus. Because several pathologic findings frequently coexist, sonography is of limited use in the diagnosis of specific abnormalities.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. E. Hann, C. M. Kim, M. Gonen, R. Barakat, P. H. Choi, and A. M. Bach Sonohysterography Compared With Endometrial Biopsy for Evaluation of the Endometrium in Tamoxifen-Treated Women J. Ultrasound Med., November 1, 2003; 22(11): 1173 - 1179. [Abstract] [Full Text] [PDF]

				P. L. Williams, S. L. Laifer-Narin, and N. Ragavendra US of Abnormal Uterine Bleeding RadioGraphics, May 1, 2003; 23(3): 703 - 718. [Abstract] [Full Text] [PDF]

				K. M. Dudiak Invited Commentary RadioGraphics, January 1, 2003; 23(1): 151 - 155. [Full Text] [PDF]

				L. E. Hann, E. M. Gretz, A. M. Bach, and S. M. Francis Sonohysterography for Evaluation of the Endometrium in Women Treated with Tamoxifen Am. J. Roentgenol., August 1, 2001; 177(2): 337 - 342. [Abstract] [Full Text] [PDF]

				M. J. E. Mourits, E. G. E. De Vries, P. H. B. Willemse, K. A. Ten Hoor, H. Hollema, and A. G. J. Van der Zee TAMOXIFEN TREATMENT AND GYNECOLOGIC SIDE EFFECTS: A REVIEW Obstet. Gynecol., May 1, 2001; 97(5): 855 - 866. [Abstract] [Full Text] [PDF]

				C. L. Kalbhen, S. M. Ascher, I. Imaoka, and J. M. Lage Imaging of Tamoxifen-induced Uterine Abnormalities Dr Ascher and colleagues respond: Radiology, December 1, 2000; 217(3): 917 - 918. [Full Text]

				S. M. Ascher, I. Imaoka, and J. M. Lage Tamoxifen-induced Uterine Abnormalities: The Role of Imaging1 Radiology, January 1, 2000; 214(1): 29 - 38. [Abstract] [Full Text]

				L. louffe Jr. Selective Estrogen Receptor Modulators (SERMs) in Clinical Practice Reproductive Sciences, January 1, 2000; 7(1_suppl): S38 - S46. [Abstract] [PDF]

				C.D.B. Love, B. B. Muir, J. B. Scrimgeour, R. C.F. Leonard, P. Dillon, and J. M. Dixon Investigation of Endometrial Abnormalities in Asymptomatic Women Treated With Tamoxifen and an Evaluation of the Role of Endometrial Screening J. Clin. Oncol., July 1, 1999; 17(7): 2050 - 2050. [Abstract] [Full Text] [PDF]

				M. FRANCHI, F. GHEZZI, N. DONADELLO, F. ZANABONI, P. BERETTA, and P. BOLIS Endometrial Thickness in Tamoxifen-Treated Patients: An Independent Predictor of Endometrial Disease Obstet. Gynecol., June 1, 1999; 93(6): 1004 - 1008. [Abstract] [Full Text] [PDF]

				R. Smith-Bindman, K. Kerlikowske, V. A. Feldstein, L. Subak, J. Scheidler, M. Segal, R. Brand, and D. Grady Endovaginal Ultrasound to Exclude Endometrial Cancer and Other Endometrial Abnormalities JAMA, November 4, 1998; 280(17): 1510 - 1517. [Abstract] [Full Text] [PDF]

				P Neven, X D Muylder, Y V Belle, R Campo, and G Vanderick Tamoxifen and the uterus BMJ, November 19, 1994; 309(6965): 1313 - 1314. [Full Text]

				M McKee On advising politicians BMJ, May 21, 1994; 308(6940): 1313 - 1313. [Full Text]